These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16650917)

  • 1. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine.
    Aguila A; Donachie AM; Peyre M; McSharry CP; Sesardic D; Mowat AM
    Vaccine; 2006 Jun; 24(24):5201-10. PubMed ID: 16650917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mucosal adjuvanticity of the oligodeoxynucleotides containing a non-methylated CpG motif on BCG and diphtheria toxoid.
    Maeyama J; Komiya T; Takahashi M; Isaka M; Goto N; Yamamoto S
    Vaccine; 2009 Feb; 27(8):1166-73. PubMed ID: 19136040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
    Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and potential application of ISCOMs in veterinary medicine.
    Morein B; Hu KF; Abusugra I
    Adv Drug Deliv Rev; 2004 Jun; 56(10):1367-82. PubMed ID: 15191787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
    McNeela EA; O'Connor D; Jabbal-Gill I; Illum L; Davis SS; Pizza M; Peppoloni S; Rappuoli R; Mills KH
    Vaccine; 2000 Dec; 19(9-10):1188-98. PubMed ID: 11137256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B.
    Pandey RS; Dixit VK
    J Drug Target; 2010 May; 18(4):282-91. PubMed ID: 19958131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
    Schulze K; Olive C; Ebensen T; Guzmán CA
    Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses.
    Smith RE; Donachie AM; Grdic D; Lycke N; Mowat AM
    J Immunol; 1999 May; 162(9):5536-46. PubMed ID: 10228035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
    J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route.
    Mowat AM; Donachie AM; Reid G; Jarrett O
    Immunology; 1991 Mar; 72(3):317-22. PubMed ID: 2026440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).
    Eyles JE; Hartley MG; Laws TR; Oyston PC; Griffin KF; Titball RW
    Microb Pathog; 2008 Feb; 44(2):164-8. PubMed ID: 17904793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
    Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
    Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori.
    Skene CD; Doidge C; Sutton P
    Vaccine; 2008 Jul; 26(31):3880-4. PubMed ID: 18547687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.
    McNeela EA; Jabbal-Gill I; Illum L; Pizza M; Rappuoli R; Podda A; Lewis DJ; Mills KH
    Vaccine; 2004 Feb; 22(8):909-14. PubMed ID: 15161067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake.
    Cibulski SP; Mourglia-Ettlin G; Teixeira TF; Quirici L; Roehe PM; Ferreira F; Silveira F
    Vaccine; 2016 Feb; 34(9):1162-71. PubMed ID: 26826546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant.
    Rydell N; Sjöholm I
    Vaccine; 2004 Mar; 22(9-10):1265-74. PubMed ID: 15003656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
    Lycke N
    Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.